Pharmaceuticals, Biotechnology and Life Sciences
Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney…
Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney…
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat…
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat…
TORONTO, April 04, 2022 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services…
TORONTO, April 04, 2022 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services…
– NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout…
Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and stroke with…
MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications Covering…
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a…